European Society of Mycobacteriology - Instituto Nacional de Saúde ...
European Society of Mycobacteriology - Instituto Nacional de Saúde ...
European Society of Mycobacteriology - Instituto Nacional de Saúde ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
PP-45<br />
Resistance, MDR and XDR <strong>of</strong> M. tuberculosis in Spain in the last years.<br />
P. Ruiz, M. Causse, F.J. Zerolo, J. Gutierrez, M. Casal<br />
Mycobacteria Reference Center. Department <strong>of</strong> Microbiology. Faculty <strong>of</strong> Medicine. HospitL “Reina S<strong>of</strong>ía” . Córdoba. Spain.<br />
Tuberculosis is among the leading causes <strong>of</strong> <strong>de</strong>ath worldwi<strong>de</strong>. The World Health Organization (WHO) estimates that<br />
32% <strong>of</strong> the world population is infected with Mycobacterium tuberculosis . The resistance to antituberculous drugs is a big<br />
problem to the control <strong>of</strong> the illness . The emergence <strong>of</strong> multidrug-resistant strains (MDR), extensively drug-resistant<br />
(XDR) and extreme drug-resistant (XXDR) strains, is a global problem that has ma<strong>de</strong> a consi<strong>de</strong>rable alarm. There is an<br />
increasing <strong>de</strong>mand to <strong>de</strong>terminate in vitro susceptibilities <strong>of</strong> clinical isolates to antimicrobial agents other than those<br />
consi<strong>de</strong>red primary drugs.<br />
The purpose <strong>of</strong> this study, was <strong>de</strong>terminate the resistance, MDR and XDR strains in our Reference Center in the four last years.<br />
Material and method<br />
We are studied 624 samples from patients suspects <strong>of</strong> tuberculosis. 355 strains <strong>of</strong> M. tuberculosis were isolates , in<br />
BACTEC MGIT 960 and Lowenstein -Jensen medium and i<strong>de</strong>ntified using Accuprobe and GENOTYPE MYCOBACTERIA.<br />
The susceptibility testing was ma<strong>de</strong> for primary drugs and: Amikacin (AK) 1.0 µg/ml; Kanamycin (K) 1 µg/ml; Capreomycin<br />
(CM) 2.5 µg/ml; Ethionamy<strong>de</strong> (ETH) 5.0 µg/ml; Ofloxacin (OF) 2.0 µg/ml; Cipr<strong>of</strong>loxacin (CI) 2 µg/ml ; Moxifloxacin (MX)<br />
2 µg/ml; Lev<strong>of</strong>loxacin (LE) 4µg/ml; Rifabutin (Rb) 0.5 µg/ml ;Rifapentine 5 µg/ml and Linezolid (Lz) 1.0 µg/ml. The Bactec<br />
MGIT technique with standart protocol was strictly followed as recommen<strong>de</strong>d,<br />
Results<br />
From 624 samples, in 355 were isolated M. tuberculosis and 55 (15,49 %) <strong>of</strong> theme were resistant to some <strong>of</strong> the antimicrobial<br />
agents studied. The resistance to streptomycin was 3´38 %, to rifampin 7,88%. ethambutol 1,12 %, isoniazid 11.26<br />
% and pyrazinami<strong>de</strong> 1,97%. A 7,6 % <strong>of</strong> strains were resistant to some <strong>of</strong> the second line drugs.The MDR was 5,6 % and<br />
the XDR 1,4 %. No XXDR were isolated.<br />
Conclusion<br />
The resistance to secondary drugs ma<strong>de</strong> necessary the in vitro studies. This method, BACTEC MGIT 960 is a reliable and<br />
rapid method to <strong>de</strong>terminate the secondary drugs.<br />
<strong>European</strong> <strong>Society</strong> <strong>of</strong> <strong>Mycobacteriology</strong> | 30 th Annual Congress | July 2009 | Porto - Portugal<br />
117